271 related articles for article (PubMed ID: 18720087)
1. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study.
Rossinen J; Harjola VP; Siirila-Waris K; Lassus J; Melin J; Peuhkurinen K; Nieminen MS
Acute Card Care; 2008; 10(4):209-13. PubMed ID: 18720087
[TBL] [Abstract][Full Text] [Related]
2. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
3. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
4. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan: a retrospective single-center case series.
Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
[TBL] [Abstract][Full Text] [Related]
6. A promising new inotrope: levosimendan.
Fotbolcu H; Duman D
Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
[TBL] [Abstract][Full Text] [Related]
7. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
[TBL] [Abstract][Full Text] [Related]
10. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
[TBL] [Abstract][Full Text] [Related]
11. Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis.
Madeira M; Caetano F; Almeida I; Fernandes A; Reis L; Costa M; Gonçalves L
Rev Port Cardiol; 2017 Sep; 36(9):619-625. PubMed ID: 28826934
[TBL] [Abstract][Full Text] [Related]
12. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure.
Bonios MJ; Terrovitis JV; Drakos SG; Katsaros F; Pantsios C; Nanas SN; Kanakakis J; Alexopoulos G; Toumanidis S; Anastasiou-Nana M; Nanas JN
Int J Cardiol; 2012 Sep; 159(3):225-9. PubMed ID: 21481958
[TBL] [Abstract][Full Text] [Related]
14. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
15. Inotropes in the management of acute heart failure.
Petersen JW; Felker GM
Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
Kivikko M; Pollesello P; Tarvasmäki T; Sarapohja T; Nieminen MS; Harjola VP
Int J Cardiol; 2016 Jul; 215():26-31. PubMed ID: 27107540
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
